With the multi-center global clinical trials trend continuing to grow, the U.S. and Canada accounted for 60.5% of sponsored trials in 2010. To deliver integrated U.S.-Canada study reviews, Pearl IRB, based in Indianapolis, and Toronto-based Trafalgar Ethics Board have joined forces.
Clinical trials are often delayed for many reasons, including contract negotiations, budgeting issues and IRB reviews. “We strive to decrease site review times by integrating our processes to provide parallel U.S. and Canadian site reviews,” said Diana Caldwell, president and CEO of Pearl IRB. “Additionally, we will partner to offer additional services including medical writing, GCP/ICH assistance and site training, all of which reach across Canada and the U.S. now.”
“Both our Canadian clients and U.S.-based sponsors are demanding higher quality and increased efficiencies in the global regulatory oversight of their clinical trials,” added Ali Thompson, director of Trafalgar Ethics Board. “By working together to provide seamless U.S.-Canada IRB reviews, we eliminate much duplication and help streamline work for our clients.”